Superworth

Supernus Pharmaceuticals SUPN

Drug Manufacturers - General, Healthcare
$36.28
−13.45%
Market cap
$2.1B
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
2.4×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$865.1M
+27% on a year ago
Net margin
−5.1%
Free cash flow yield
4.1%

Supernus Pharmaceuticals trades at 2.4× sales. Its trailing earnings are negative, so it has no PE. Revenue was $865.1M over the last twelve months, up 27% on a year earlier with a −5% net margin.

Charts

Financials

Income statement for SUPN, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$164.3M−2%$143.6M−7%$168.3M+24%$175.7M+14%$174.2M+6%$149.8M+4%$165.5M−2%$192.1M+9%$211.6M+22%$207.7M+39%$219.1M+32%$226.8M+18%
Cost of revenue$19.6M−15%$16.3M−31%$17.9M−15%$17.6M−10%$26.1M+33%$15.8M−3%$16.8M−6%$19M+8%$23M−12%$23.4M+48%$33.7M+100%$27M+43%
Gross profit$144.7M+0%$127.3M−2%$150.4M+31%$158.1M+18%$148.1M+2%$134.1M+5%$148.6M−1%$173.1M+10%$188.6M+27%$184.3M+38%$185.4M+25%$199.8M+15%
R&D$23.3M+31%$24.9M+18%$26.2M+7%$29M+28%$28.6M+23%$26.9M+8%$22.1M−16%$29.4M+1%$27.8M−3%$39.4M+47%$29.5M+33%$25.8M−12%
SG&A$81.3M+10%$86.5M+1%$85.9M−1%$69.8M−16%$79.4M−2%$89.9M+4%$93.6M+9%$179.7M+158%$122.4M+54%$125.2M+39%$133.6M+43%$128.1M−29%
−$996K−$3.2M$22.6M$40.8M+402%$21.4M−$10.3M+225%$12.1M−46%−$60.2M−$3.9M−$8.3M−19%−$58M$21.2M
Interest expense−$1.1M+33%$0$0$0$0n/a$0$0$0n/a$2.3M$718K
Pre-tax income$990K−97%$243K−97%$26.3M$44.9M+355%$26.4M+2565%−$5.8M$16.7M−37%−$58M−$1.9M−$6M+2%−$57.6M$22.7M
−$185K$119K$6.4M$6.4M−75%$11.1M$6M+4939%−$5.8M−$12.8M$2.2M−80%−$3.7M$723K$1.8M
Net income$1.2M−95%$124K−99%$19.9M$38.5M$15.3M+1205%−$11.8M$22.5M+13%−$45.1M−$4.1M−$2.3M−81%−$58.4M$20.9M
$0.02−95%$0.00$0.36$0.69$0.27+1250%−$0.21$0.40+11%−$0.80−$0.07−$0.04−81%−$1.01$0.35
55.3M−11%55.6M−11%55.7M+2%56M+3%56.5M+2%55.9M+0%56.6M+2%56.6M+1%57.4M+2%57.6M+3%58.1M+3%59.5M+5%

Revenue: Q1 FY11: 6 months less the 3 months printed beside them.

Gross profit: 54 periods, Q2 FY13 to Q3 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: 8 periods, Q4 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 12 periods, Q4 FY11 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. 3 periods, Q4 FY12 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Supernus Pharmaceuticals' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
SUPNSupernus Pharmaceuticals$2.1Bn/m23.8×2.4×+27%−5.1%
HRMYHarmony Biosciences$2.2B12.3×13.8×2.3×+24%18.9%
PBHPrestige Consumer Healthcare$2.4B13.9×15.3×2.1×−1%15.6%
ANIPANI Pharmaceuticals$1.6B15.0×57.5×1.7×+31%11.1%
NRIXNurix Therapeutics$2.8B11.1×11.0×4.0×n/m42.0%
PAHCPhibro Animal Health$1.6B15.9×21.5×1.0×+17%6.6%
PCRXPacira BioSciences$1.5B104×65.7×1.9×+6%2.0%
ANABAnaptysbio$1.4B10.3×99.3×n/mn/mn/m
OMEROmeros$1.3B11.7×11.7×n/mn/mn/m
OGNOrganon$3.6B18.2×6.0×0.6×−3%3.5%
LQDALiquidia$3.7B30.1×49.4×8.3×n/m30.7%
Peer median$1.9B14.5×18.4×2.0×+11%13.3%

More on Supernus Pharmaceuticals

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .